ЖурналыПодпискаАрхивКнигиПроектыО насРекламаДоставка/ОплатаКонтакты
+7 (495) 482-43-29
  • Главная
  • / Журналы
  • / Вернуться в журнал
  • / Содержание номера
  • / Статья
Модифицируемые факторы риска болезни Альцгеймера

Модифицируемые факторы риска болезни Альцгеймера

Авторы:
Екатерина Владимировна Махнович,
Екатерина Андреевна Коваленко,
Нина Алексеевна Осиновская,
Анастасия Игоревна Шутикова,
Ирина Ивановна Ковалёва,
Анна Николаевна Боголепова

Журнал: Журнал неврологии и психиатрии им. С.С. Корсакова. 2026;126(10):7-15.

DOI: 10.17116/jnevro20261261017

Прочитано: 149 раз

Резюме

Болезнь Альцгеймера представляет собой одну из ведущих медико-социальных проблем современности и является наиболее распространенной причиной деменции, которая приводит к инвалидизации пациентов. В условиях отсутствия этиотропной терапии приоритетной задачей медицинского сообщества становится первичная и вторичная профилактика, основанная на контроле детерминирующих факторов развития болезни Альцгеймера. В связи с чем последние годы все больше внимания уделяется изучению модифицируемых факторов риска, воздействие на которые на протяжении всей жизни может потенциально предотвратить до 45% случаев деменции. В статье представлен обзор 14 факторов риска развития деменции и рассмотрены патогенетические механизмы, опосредующие влияние данных факторов на развитие болезни Альцгеймера.

Ключевые слова

  • когнитивные нарушения
  • деменция
  • болезнь Альцгеймера
  • нейродегенеративные заболевания
  • факторы риска
  • патогенез

Конфликт интересов

Авторы заявляют об отсутствии конфликта интересов.

Дата поступления: 23.04.2026

Дата принятия в печать: 23.05.2026

Дата публикации: 03.11.2026

Литература / References
  1. Livingston G, Huntley J, Sommerlad A, et al. Dementia prevention, intervention, and care: 2020 report of the Lancet Commission. Lancet. 2020;396(10248):413-446. https://doi.org/10.1016/S0140-6736(20)30367-6
  2. Livingston G, Huntley J, Liu KY, et al. Dementia prevention, intervention, and care: 2024 report of the Lancet standing Commission. Lancet. 2024;404(10452):572-628. https://doi.org/10.1016/S0140-6736(24)01296-0
  3. Stern Y. Cognitive reserve in ageing and Alzheimer’s disease. Lancet. Neurology. 2012;11(11):1006-1012. https://doi.org/10.1016/S1474-4422(12)70191-6
  4. Liu Y, Julkunen V, Paajanen T, et al. Education increases reserve against Alzheimer’s disease—evidence from structural MRI analysis. Neuroradiology. 2012;54(9):929-938. https://doi.org/10.1007/s00234-012-1005-0
  5. Lennon MJ, Makkar SR, Crawford JD, Sachdev PS. Midlife hypertension and Alzheimer’s disease: a systematic review and meta-analysis. Journal of Alzheimer’s disease. 2019;71(1):307-316. https://doi.org/10.3233/JAD-190474
  6. Walker KA, Sharrett AR, Wu A, et al. Association of midlife to late-life blood pressure patterns with incident dementia. JAMA. 2019;322(6):535-545. https://doi.org/10.1001/jama.2019.10575
  7. Santisteban MM, Iadecola C, Carnevale D. Hypertension, neurovascular dysfunction, and cognitive impairment. Hypertension. 2023;80(1):22-34. https://doi.org/10.1161/HYPERTENSIONAHA.122.18085
  8. Mortensen KN, Sanggaard S, Mestre H, et al. Impaired glymphatic transport in spontaneously hypertensive rats. Journal of neuroscience. 2019;39(32):6365-6377. https://doi.org/10.1523/JNEUROSCI.1974-18.2019
  9. de Havenon A, Falcone G, Rivier C, et al. Impact of sleep quality and physical activity on blood pressure variability. PLoS One. 2024;19(4):e0301631. https://doi.org/10.1371/journal.pone.0301631
  10. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Archives of internal medicine. 2002;162(18):2046-2052. https://doi.org/10.1001/archinte.162.18.2046
  11. Yasar S, Xia J, Yao W, et al. Antihypertensive drugs decrease risk of Alzheimer disease: Ginkgo Evaluation of Memory Study. Neurology. 2013;81(10):896-903. https://doi.org/10.1212/WNL.0b013e3182a35228
  12. Chuang YF, An Y, Bilgel M, et al. Midlife adiposity predicts earlier onset of Alzheimer’s dementia, neuropathology and presymptomatic cerebral amyloid accumulation. Molecular psychiatry. 2016;21(7):910-915. https://doi.org/10.1038/mp.2015.129
  13. Terzo S, Amato A, Mulè F. From obesity to Alzheimer’s disease through insulin resistance. Journal of diabetes and its complications. 2021;35(11):108026. https://doi.org/10.1016/j.jdiacomp.2021.108026
  14. Flores-Cordero JA, Pérez-Pérez A, Jiménez-Cortegana C, et al. Obesity as a Risk Factor for Dementia and Alzheimer’s Disease: The Role of Leptin. International journal of molecular sciences. 2022;23(9):5202. https://doi.org/10.3390/ijms23095202
  15. Cao X, Peng H, Hu Z, et al. Exploring the global impact of obesity and diet on dementia burden: the role of national policies and sex differences. Geroscience. 2025;47(1):1345-1360. https://doi.org/10.1007/s11357-024-01457-w
  16. Lee S, Byun MS, Yi D, et al. Body mass index and two-year change of in vivo Alzheimer’s disease pathologies in cognitively normal older adults. Alzheimer’s research & therapy. 2023;15(1):108. https://doi.org/10.1186/s13195-023-01259-w
  17. Kang SY, Kim YJ, Jang W, et al. Body mass index trajectories and the risk for Alzheimer’s disease among older adults. Scientific reports. 2021;11(1):3087. https://doi.org/10.1038/s41598-021-82593-7
  18. Chen X, Hui L, Geiger JD. Role of LDL cholesterol and endolysosomes in amyloidogenesis and Alzheimer’s disease. Journal of neurology & neurophysiology. 2014;5(5):236. https://doi.org/10.4172/2155-9562.1000236
  19. Lee M, Lee K.J, Kim J, et al. Low-density lipoprotein cholesterol levels and risk of incident dementia: a distributed network analysis using common data models. Journal of neurology, neurosurgery, and psychiatry. 2025;96:981-989. https://doi.org/10.1136/jnnp-2024-334708
  20. Zhou Z, Moran C, Murray AM, et al. Association of Year-to-Year Lipid Variability With Risk of Cognitive Decline and Dementia in Community-Dwelling Older Adults. Neurology. 2025;104(4):e210247. https://doi.org/10.1212/WNL.0000000000210247
  21. Zhang Z, Ma L, Huang L, et al. Association of low-density lipoprotein/high-density lipoprotein ratio with cognition, Alzheimer’s disease biomarkers and brain structure. Frontiers in aging neuroscience. 2025;17:1457160. https://doi.org/10.3389/fnagi.2025.1457160
  22. Roriz-Filho JS, Sá-Roriz TM, Rosset I, et al. (Pre)diabetes, brain aging, and cognition. Biochim Biophys Acta. 2009;1792(5):432-443. https://doi.org/10.1016/j.bbadis.2008.12.003
  23. Bedse G, Di Domenico F, Serviddio G, Cassano T. Aberrant insulin signaling in Alzheimer’s disease: current knowledge. Frontiers in neuroscience. 2015;9:204. https://doi.org/10.3389/fnins.2015.00204
  24. Cai HY, Wang ZJ, Hölscher C, et al. Lixisenatide attenuates the detrimental effects of amyloid β protein on spatial working memory and hippocampal neurons in rats. Behavioural brain research. 2017;318:28-35. https://doi.org/10.1016/j.bbr.2016.10.033
  25. Potenza MA, Sgarra L, Desantis V, et al. Diabetes and Alzheimer’s disease: might mitochondrial dysfunction help deciphering the common path? Antioxidants (Basel). 2021;10(8):1257. https://doi.org/10.3390/antiox10081257
  26. Kumar V, Kim SH, Bishayee K. Dysfunctional Glucose Metabolism in Alzheimer’s Disease Onset and Potential Pharmacological Interventions. International journal of molecular sciences. 2022;23(17):9540. https://doi.org/10.3390/ijms23179540
  27. Jeong S, Lin L, Leone AP, Hsu YH. Type 2 diabetes and late-onset Alzheimer’s disease and related dementia: a longitudinal cohort study integrating polygenic risk score. Journal of Alzheimer’s disease. 2025;105(1):107-119. https://doi.org/10.1177/13872877251326107
  28. Yoon JH, Hwang J, Son SU, et al. How can insulin resistance cause Alzheimer’s disease? International journal of molecular sciences. 2023;24(4):3506. https://doi.org/10.3390/ijms24043506
  29. Wang K, Zhao S, Lee EK, et al. Risk of Dementia Among Patients With Diabetes in a Multidisciplinary, Primary Care Management Program. JAMA network open. 2024;7(2):e2355733. https://doi.org/10.1001/jamanetworkopen.2023.55733
  30. Breunig JJ, Guillot-Sestier MV, Town T. Brain injury, neuroinflammation and Alzheimer’s disease. Frontiers in aging neuroscience. 2013;5:26. https://doi.org/10.3389/fnagi.2013.00026
  31. Sun B, Li L, Harris OA, et al. Blood-brain barrier disruption: a pervasive driver and mechanistic link between traumatic brain injury and Alzheimer’s disease. Translational neurodegeneration. 2025;14:16. https://doi.org/10.1186/s40035-025-00478-5
  32. de Bruin H, Groot C, Kamps S, et al. Amyloid-β and tau deposition in traumatic brain injury: a study of Vietnam War veterans. Brain communications. 2025;7(1):fcaf009. https://doi.org/10.1093/braincomms/fcaf009
  33. Readman MR, Littlejohn J, Dodd I, et al. Hearing loss as a risk factor for dementia: a systematic review and meta-analysis from a global perspective. Aging & mental health. 2025;29(10):1831-1844. https://doi.org/10.1080/13607863.2025.2515180
  34. Wang HF, Zhang W, Rolls ET, et al. Hearing impairment is associated with cognitive decline, brain atrophy and tau pathology. EBioMedicine. 2022;86:104336. https://doi.org/10.1016/j.ebiom.2022.104336
  35. Warren JD, Hardy CJ, Johnson J, et al. Dementia is an auditory brain disorder. Alzheimer’s Dementia. 2023;19:e070951. https://doi.org/10.1002/alz.070951
  36. Sinha UK, Hollen KM, Rodriguez R, Miller CA. Auditory system degeneration in Alzheimer’s disease. Neurology. 1993;43(4):779-785. https://doi.org/10.1212/wnl.43.4.779
  37. Topiwala A, Allan CL, Valkanova V, et al. Moderate alcohol consumption as risk factor for adverse brain outcomes and cognitive decline: longitudinal cohort study. BMJ. 2017;357:j2353. https://doi.org/10.1136/bmj.j2353
  38. Kamal H, Tan GC, Ibrahim SF, et al. Alcohol Use Disorder, Neurodegeneration, Alzheimer’s and Parkinson’s Disease: Interplay Between Oxidative Stress, Neuroimmune Response and Excitotoxicity. Frontiers in cellular neuroscience. 2020;14:282. https://doi.org/10.3389/fncel.2020.00282
  39. Lin JY, Zhang HB, Luo L, et al. Glymphatic system dysfunction in alcohol use disorder: Current understanding and future directions. World journal of psychiatry. 2025;15(10):107936. https://doi.org/10.5498/wjp.v15.i10.107936
  40. Monnig M, Shah K. Linking alcohol use to Alzheimer’s disease: Interactions with aging and APOE along immune pathways. Medical research archives. 2024;12(8):10.18103/mra.v12i8.5228. https://doi.org/10.18103/mra.v12i8.5228
  41. Anstey KJ, von Sanden C, Salim A, O’Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. American journal of epidemiology. 2007;166(4):367-378. https://doi.org/10.1093/aje/kwm116
  42. Addissouky TA, El Sayed IET, Ali MMA et al. Oxidative stress and inflammation: elucidating mechanisms of smoking-attributable pathology for therapeutic targeting. Bulletin of the National Research Centre. 2024;48:16. https://doi.org/10.1186/s42269-024-01174-6
  43. Naik P, Fofaria N, Prasad S, et al. Oxidative and pro-inflammatory impact of regular and denicotinized cigarettes on blood brain barrier endothelial cells: is smoking reduced or nicotine-free products really safe? BMC neuroscience. 2014;15:51. https://doi.org/10.1186/1471-2202-15-51
  44. Durazzo TC, Meyerhoff DJ, Murray DE. Comparison of regional brain perfusion levels in chronically smoking and non-smoking adults. International journal of environmental research and public health. 2015;12(7):8198-8213. https://doi.org/10.3390/ijerph120708198
  45. Markunas CA, Xu Z, Harlid S, et al. Identification of DNA methylation changes in newborns related to maternal smoking during pregnancy. Environmental health perspectives. 2014;122(10):1147-1153. https://doi.org/10.1289/ehp.1307892
  46. Kisby G, Raber J. World no-tobacco: effects of second-hand smoke (SHS) and vapors on the developing and adult brain. Frontiers in pharmacology. 2025;16:1466332. https://doi.org/10.3389/fphar.2025.1466332
  47. Akyuz E, Arulsamy A, Aslan FS, et al. An expanded narrative review of neurotransmitters on Alzheimer’s disease: the role of therapeutic interventions on neurotransmission. Molecular neurobiology. 2025;62(2):1631-1674. https://doi.org/10.1007/s12035-024-04333-y
  48. Hasan SMN, Clarke C, Strand T, Bambico FR. Putative pathological mechanisms of late-life depression and Alzheimer’s disease. Brain research. 2023;1813:148423. https://doi.org/10.1016/j.brainres.2023.148423
  49. Dintica CS, Habes M, Schreiner PJ, et al. Trajectories in depressive symptoms and midlife brain health. Translational psychiatry. 2024;14(1):169. https://doi.org/10.1038/s41398-024-02883-2
  50. Wang GH, Chen WH, Chang SH, et al. Association between first-line antidepressant use and risk of dementia in older adults: a retrospective cohort study. BMC geriatrics. 2023;23(1):825. https://doi.org/10.1186/s12877-023-04475-z
  51. Mo M, Abzhandadze T, Hoang MT, et al. Antidepressant use and cognitive decline in patients with dementia: a national cohort study. BMC medicine. 2025;23(1):82. https://doi.org/10.1186/s12916-025-03851-3
  52. Dafsari FS, Jessen F. Depression-an underrecognized target for prevention of dementia in Alzheimer’s disease. Translational psychiatry. 2020;10(1):160. https://doi.org/10.1038/s41398-020-0839-1
  53. Zhang X, Li Q, Cong W, et al. Effect of physical activity on risk of Alzheimer’s disease: a systematic review and meta-analysis of twenty-nine prospective cohort studies. Ageing research reviews. 2023;92:102127. https://doi.org/10.1016/j.arr.2023.102127
  54. Beckett MW, Ardern CI, Rotondi MA. A meta-analysis of prospective studies on the role of physical activity and the prevention of Alzheimer’s disease in older adults. BMC geriatrics. 2015;15:9. https://doi.org/10.1186/s12877-015-0007-2
  55. Zhao R. Exercise mimetics: a novel strategy to combat neuroinflammation and Alzheimer’s disease. Journal of neuroinflammation. 2024;21:40. https://doi.org/10.1186/s12974-024-03031-9
  56. Lu Y, Bu FQ, Wang F, et al. Recent advances on the molecular mechanisms of exercise-induced improvements of cognitive dysfunction. Translational neurodegeneration. 2023;12:9. https://doi.org/10.1186/s40035-023-00341-5
  57. Del Pozo Cruz B, Ahmadi M, Naismith SL, Stamatakis E. Association of Daily Step Count and Intensity With Incident Dementia in 78 430 Adults Living in the UK. JAMA neurology. 2022;79(10):1059-1063. https://doi.org/10.1001/jamaneurol.2022.2672
  58. Yau WW, Kirn DR, Rabin JS, et al. Physical activity as a modifiable risk factor in preclinical Alzheimer’s disease. Nature medicine. 2025;31(12):4075-4083. https://doi.org/10.1038/s41591-025-03955-6
  59. Zheng C, Zeng R, Wu G, et al. Beyond vision: A view from eye to Alzheimer’s disease and dementia. The journal of prevention of Alzheimer’s disease. 2024;11(2):469-483. https://doi.org/10.14283/jpad.2023.118
  60. Ferguson EL, Thoma M, Buto PT, et al. Visual Impairment, Eye Conditions, and Diagnoses of Neurodegeneration and Dementia. JAMA network open. 2024;7(7):e2424539. https://doi.org/10.1001/jamanetworkopen.2024.24539
  61. Lee GI, Chi SA, Kim K, et al. Visual impairment increases the risk of dementia, especially in young males in a 12-year longitudinal follow-up study of a national cohort. Scientific reports. 2021;11(1):11393 https://doi.org/10.1038/s41598-021-91026-4
  62. Varadaraj V, Munoz B, Deal JA, et al. Association of Vision Impairment With Cognitive Decline Across Multiple Domains in Older Adults. JAMA network open. 2021;4(7):e2117416. https://doi.org/10.1001/jamanetworkopen.2021.17416
  63. Liu X, Guan Z, Liang S, et al. Associations of cataract, cataract surgery with dementia risk: A systematic review and meta-analysis of 448,140 participants. European journal of clinical investigation. 2024;54(2):e14113. https://doi.org/10.1111/eci.14113
  64. Shafighi K, Villeneuve S, Rosa-Neto P, et al. Social isolation is linked to classical risk factors of Alzheimer’s disease-related dementias. PLoS One. 2023;18(2):e0280471. https://doi.org/10.1371/journal.pone.0280471
  65. White S, Mauer R, Lange C, et al; Alzheimer’s Disease Neuroimaging Initiative. The effect of plasma cortisol on hippocampal atrophy and clinical progression in mild cognitive impairment. Alzheimer’s & dementia (Amsterdam, Netherlands). 2023;15(3):e12463. https://doi.org/10.1002/dad2.12463
  66. Shen C, Rolls ET, Cheng W, et al. Associations of Social Isolation and Loneliness With Later Dementia. Neurology. 2022;99(2):e164-e175. https://doi.org/10.1212/WNL.0000000000200583
  67. Huang QM, Zhang PD, Shen D, et al. Analysis of changes in social isolation, loneliness, or both, and subsequent cognitive function among older adults: Findings from a nationwide cohort study. Alzheimer’s & dementia: the journal of the Alzheimer’s Association. 2024;20(8):5674-5683. https://doi.org/10.1002/alz.14080
  68. Olloquequi J, Díaz-Peña R, Verdaguer E, et al. From inhalation to neurodegeneration: air pollution as a modifiable risk factor for Alzheimer’s disease. International journal of molecular sciences. 2024;25(13):6928. https://doi.org/10.3390/ijms25136928
  69. Balboni E, Filippini T, Crous-Bou M, et al. The association between air pollutants and hippocampal volume from magnetic resonance imaging: a systematic review and meta-analysis. Environmental research. 2022;204(Pt A):111976. https://doi.org/10.1016/j.envres.2021.111976
  70. Huang X, Steinmetz J, Marsh EK, et al. A systematic review with a Burden of Proof meta-analysis of health effects of long-term ambient fine particulate matter (PM2.5) exposure on dementia. Nature aging. 2025;5(5):897-908. https://doi.org/10.1038/s43587-025-00844-y
slide-cover

Рекомендуем статьи по данной теме:

Церебральная амилоидная ангиопатия.Журнал неврологии и психиатрии им. С.С. Корсакова. 2026;126(10):24-31

Умеренное когнитивное расстройство как гетерогенное состояние: от алгоритмов диагностики — к дифференцированной терапии.Журнал неврологии и психиатрии им. С.С. Корсакова. 2026;126(9):42-51

Современный взгляд на немедикаментозную коррекцию когнитивных нарушений.Журнал неврологии и психиатрии им. С.С. Корсакова. 2026;126(8):59-65

Молекулярные и системные механизмы когнитивных нарушений, ассоциированных с коронавирусной инфекцией.Журнал неврологии и психиатрии им. С.С. Корсакова. 2026;126(8):40-50

Боль и когнитивные нарушения: от сенсорной индифферентности к нейродегенеративному фенотипу.Журнал неврологии и психиатрии им. С.С. Корсакова. 2026;126(6):23-28

Двунаправленные связи между депривацией сна и развитием нейродегенеративных заболеваний.Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2026;126(5-2):74-80

Когнитивные нарушения после COVID-ассоциированной пневмонии: результаты проспективного когортного исследования факторов риска.Журнал неврологии и психиатрии им. С.С. Корсакова. 2026;126(5):43-47

Когнитивные нарушения у 2775 амбулаторных пациентов с артериальной гипертонией и ИБС: связь между показателями выживаемости и смертности по данным пятилетнего наблюдения.Кардиологический вестник. 2026;21(2):46-56

Начальные признаки когнитивных нарушений: определение, критерии диагностики.Журнал неврологии и психиатрии им. С.С. Корсакова. Спецвыпуски. 2026;126(4-2):23-28

Новый взгляд на биомаркеры крови у пациентов с болезнью Альцгеймера.Журнал неврологии и психиатрии им. С.С. Корсакова. 2025;125(12):7-13

Издательство «Медиа Сфера»
РекламаДоставка/ОплатаО насКонтактыОбучение для редакцийПолитика конфиденциальностиПолитика обработки персональных данныхПубличная оферта на реализацию издательской продукции
ЖурналыПодпискаАрхивКнигиПроекты
  • RuStore

© 1998-2026

  • Телефоны издательства:

  • +7 (495) 482-41-18
  • +7 (495) 482-43-29

  • Прямой телефон отдела подписки
    (только по вопросам заказов и доставки журналов)

  • +7 (800) 250-18-12

  • пн-пт с 10:00 до 18:00

  • Telegram
  • VK
info@mediasphera.ru

  • Почтовый адрес:

  • Издательство «Медиа Сфера»,
    а/я 54, Москва, Россия, 127238

  • RuStore

© 1998-2026